



43<sup>rd</sup> Executive Board meeting  
21-22 November 2023  
Santiago Dantas room  
Itamaraty Palace  
Brasilia, Brazil

Resolution n°4  
Area for Intervention: Enabling access to monoclonal antibodies  
to treat and prevent infectious diseases in LMICs

Having considered the analysis provided by the Secretariat, as set out in document UNITAID/EB43/2023/11, together with the recommendations of the Policy and Strategy Committee (PSC) presented to EB43 by the Chair of the PSC;

The Executive Board supports the need for Unitaid to focus strategically on "*Enabling access to monoclonal antibodies to treat and prevent infectious diseases in LMICs*", with a view to contributing to global targets set out by the World Health Organization and the Sustainable Development Goals.

Acknowledging the PSC's recommendation to implement this Area for Intervention (AFI) through a phased approach, the Board supports aligning initial investments in Phase 1 with the near-term opportunities identified in UNITAID/EB43/2023/11 and requests the Secretariat to launch appropriate calls for proposals within this AFI.

The Secretariat will keep the PSC updated on the implementation of Phase 1 and will provide its assessment regarding opportunities for Unitaid to launch further work within this AFI. The Secretariat's updates will be informed by the initial work, emerging evidence, partner plans and consideration of whether scalability goals are achievable, together with any other relevant matters. The launch of further investments will be on the advice of the PSC, taking into account the minuted deliberations that took place during the 43<sup>rd</sup> Executive Board on this topic.

A handwritten signature in black ink, appearing to read "Marisol", is written over a horizontal line.

Marisol Touraine  
Chair of the Unitaid Executive Board  
Date: 22 November 2023